Diagnostic and Therapeutic Landscapes of Prostate Cancer

Introduction to Prostate Anatomy and Clinical Significance

• The prostate is a small gland that is essential to the male reproductive system.

• Its physiological function is to produce a milky fluid that, when mixed with sperm, creates semen.

• Prostate cancer is primarily classified as an adenocarcinoma.

• Although it is one of the most prevalent cancers in men, it also affects trans women and non-binary individuals who possess a prostate.

• The speaker recounts a specific laboratory incident where a colleague (described as a "dinosaur" or "boomer") was confused by a prostate sample arriving with a female name on the sticker, highlighting the necessity of clinical mindfulness regarding gender and anatomy in the diagnostic process.

Epidemiology and Risk Factors

• Incidence and age: Prostate cancer occurs predominantly in individuals aged $50$ and older.

• Global variation: Rates vary significantly across the globe. These are generally lower in many Asian countries but significantly higher among black individuals.

• Genetic and Environmental Interaction: Research suggests that the risk of the disease reflects an interaction between inherited susceptibility and modifiable environmental exposures.

• Moving to Western countries: Studies tracking Asian immigrants in the United States show higher prostate cancer rates compared to those in their home countries. This trend indicates that lifestyle factors—specifically diet, body weight, and physical activity—play a major role.

• Westernized diet: High-fat, Western-style diets are associated with elevated risks, though some studies present mixed results on how dietary influence specifically drives the disease.

• Family history: Individuals with a first-degree relative (specifically a brother/sibling) diagnosed with prostate cancer have a $2.5$-fold increased risk of developing the disease.

• Genetics: Known germline mutations that increase risk include:

  • $HoxB13$

  • $\text{BRCA1}$ and $\text{BRCA2}$

  • $ATM$

  • $CHECK–2$

  • Lynch syndrome-associated mutations.

Cellular Signaling Pathways and Genomic Stability

• Androgen dependency: Prostate cancer cells typically depend on androgens (male hormones) for growth and survival.

• Signaling Pathways: Targeted therapies often focus on the following central pathways:

  • Androgen receptor (AR) signaling pathway: Androgens bind to receptors to form a DNA-protein complex that activates genes responsible for male characteristics.

  • $PTEN / PI3K / AKT$ pathway: Regulates cell metabolism, growth, and survival. Loss of $PTEN$ function or activation of $PI3K/AKT$ genes often drives tumor development, frequently in combination with the oncogene $RAS$.

  • $TP53$: Known as the "Guardian" of the cells, this tumor suppressor gene encodes the $P53$ protein, regulating the cell cycle transition from the $G1$ to the $S$ phase.

• Mechanisms of $TP53$: Under normal conditions, $P53$ triggers apoptosis or pauses the cycle for DNA repair. Mutations lead to a stabilized version of the protein that accumulates in the cell nucleus, detectable through immunohistochemistry (IHC).

  • $TP53$ Mutation Prevalence: Rare in early stages, but picked up in $20\%\text{--}40\%$ of advanced cases.

  • Prognosis: Accumulation of mutated $P53$ is associated with poorer prognosis and acts as a biomarker for aggressive disease.

Clinical Presentation and Symptomatology

• Urinary symptoms: Clinicians evaluate symptoms including increased frequency, locturia (waking at night to urinate), and urine hesitancy.

• Genitourinary complaints:

  • Hematuria: Blood in the urine.

  • Dysuria: Painful urination.

• Benign Prostatic Hyperplasia (BPH): Many of the above symptoms are also associated with BPH, which is a non-cancerous enlargement of the prostate.

• Systemic signs: Weight loss, bone pain, and fatigue are suggestive of advanced or metastatic prostate cancer.

The Diagnostic Process and Clinical Examinations

• Clinical Review: Diagnosis begins with a review of family history regarding prostate or other cancers and assessing for known germline mutations.

• Digital Rectal Exam (DRE): A critical diagnostic component used to assess:

  • Size of the gland.

  • Symmetry (asymmetry between left and right lobes is suspicious).

  • Consistency of the tissue (presence of nodules).

• Limitations of DRE: While invaluable for identifying abnormalities, it cannot be used as the sole screening method and serves primarily to guide the decision to conduct further tests (e.g., biopsy).

Prostate-Specific Antigen (PSA) as a Biomarker

• Usage: Total PSA is a tool for early detection and monitoring, but results must be evaluated against age-specific benchmarks, as PSA levels naturally increase with age.

• High Risk Thresholds: People with PSA levels above the median for their age group face elevated risks for aggressive disease.

• Low Risk Benchmarks:

  • Age $60$ or older with PSA < 1.0\,ng/mL.

  • Age $75$ or older with PSA < 3.0\,ng/mL.

• Advanced Metrics:

  • PSA Doubling Time and Velocity: Indicate how rapidly levels are rising, helping assess aggressiveness and response to therapy.

  • PSA Density: Calculated as $PSA\,Density = \frac{\text{Serum Level of PSA}}{\text{Prostate Volume}}$ (volume determined by MRI).

• Diagnostic Dilemma: PSA screening causes controversy due to reliability issues:

  • False Positives: Suggest cancer where none exists, leading to unnecessary biopsies.

  • False Negatives: Missing roughly $1/7$ cases of prostate cancer.

  • Slow-growing cancers: May detect cancers that would never never cause harm, leading to over-treatment.

UK Screening Policies and the TRANSFORM Trial

• Population Screening: There is currently no established population-wide screening program for prostate cancer in the UK because risk-benefit debates are ongoing.

• Targeted Screening Proposal (Late 2025): In November, the UK National Screening Committee opened a consultation on a targeted approach.

  • Eligibility: Individuals aged $45\text{--}61$ with confirmed $\text{BRCA1}$ or $\text{BRCA2}$ mutations.

  • Frequency: Targeted PSA screening offered every $2$ years.

• TRANSFORM Trial: A major study gathering data to determine if targeted screening based on genetic risk, ethnicity, or family history should be expanded.

Advanced Imaging and Biopsy Methodology

• Multi-parametric MRI (MP MRI): Now the first-line investigation for suspected prostate cancer. It uses several sequences to highlight suspicious areas and has shifted the pathway from random sampling to precise targeted biopsies.

• Biopsy Techniques:

  • Transrectal Biopsy: Older method involving the rectum.

  • Transperineal Biopsy: Preferred modern method with a significantly lower risk of infection and sepsis.

• Biopsy Procedure: Involves taking $10\text{--}20$ cores ($10$ from each lobe).

• Limitations: A negative biopsy does not completely exclude cancer; if the PSA continues to rise, ongoing evaluation is required.

Histopathology and Immunohistochemistry

• Histological Challenges: Small cores provide limited tissue; malignant cells can be intermingled with benign ones. Benign conditions can mimic cancer.

• Diagnostic Cues:

  • Basal Cells: Remained in benign glands; absent in cancerous glands.

  • Perineural Invasion: Strong evidence of prostate cancer.

• Ancillary Testing: Immunohistochemistry (IHC) markers include:

  • AMCR: Expressed in prostate cancer (though detection rates vary).

  • Basal cell markers: Used to differentiate malignant from benign tissue.

• Cost Constraints: A $500\,\mu L$ vial of antibody can cost over $\pounds 300$. Because handling $20$ cores means $20$ slides, IHC is used selectively on glands where morphology is unclear to conserve NHS resources.

Digital Pathology and Artificial Intelligence (AI)

• Limitations of Manual exams: Examining slides manually can take up to $1\,\text{hour}$ per slide, totaling $20\,\text{hours}$ per patient.

• Digital Pathology Advantage: AI identifies and measures cancer on slides in minutes.

• Betsy Caballetta Health Board Study: Became the first UK health board to implement AI for prostate cancer in December $2021$ using the IBEX system.

• IBEX/AI Results: The system demonstrates $99.96\%$ accuracy in detecting small areas of cancer. It acts as a "second pair of eyes," identifying malignancy probabilities and highlighting "hot spots" (red areas) for pathologists to review.

• Impact: AI helps alleviate the shortage of consultant pathologists and reduces the subjectivity inherent in grading.

The Gleason Grading System

• Purpose: Categorizes tumors into five grades based on glandular differentiation.

  • Grade $1$: Well-differentiated, uniform round neoplastic glands neatly arranged.

  • Grade $5$: Lack of differentiation; cancer cells infiltrate stroma in cords, sheets, or nests.

• Scoring: The Gleason Score is the sum of the primary (predominant) grade and the secondary (next most common) grade.

  • Example: Primary grade $3$ + Secondary grade $4$ = Gleason Score $7$.

• Prognostic Grouping:

  • Scores $2\text{--}6$: Well-differentiated, excellent prognosis.

  • Score $7$: Moderate to poor differentiation.

  • Score $8\text{--}10$: Poorly differentiated/undifferentiated, aggressive, harder to cure.

The Predict Prostate Clinical Decision Tool

• Background: Launched by Cambridge researchers to address variability in treatment advice for the $80\%$ of non-metastatic cases.

• Methodology: Analyzes data from over $12,000$ men across two international cohorts to provide personalized assessments of mortality risk.

• Impact: Used more than $50,000$ times in over $110$ countries. Clinical studies show a $30\%$ reduction in unnecessary treatment recommendations.

• Endorsement: Formally endorsed by the National Institutes for Health and Clinical Excellence (NICE).

Management and Treatment of Localized Cancer

• Options for Localized Disease:

  • Radical prostatectomy (removal of the gland), including robotically-assisted surgery.

  • External beam radiotherapy.

  • Active Surveillance: Recommended for low-risk (Gleason $\leq 6$) or intermediate-risk cases. Includes regular PSA monitoring and repeat MRI.

  • Brachytherapy: Targeted radiotherapy involving direct placement of radioactive sources inside the prostate.

• Side Effects: Common issues include incontinence and sexual dysfunction; older patients often prefer radiotherapy to avoid surgical risks.

Hormonal Deprivation and Targeted Therapies

• Androgen Deprivation Therapy (ADT): Aims to reduce androgen levels or block their effects.

  • Orchidectomy: Permanent surgical removal of the testes.

  • Medication (Mainstream): GnRH or LHRH agonists switch off testosterone production. These can cause a "testosterone flare," managed by short courses of anti-androgen drugs.

• Hormonal Inhibitors:

  • Androgen receptor blockers: Prevent testosterone from activating the receptor.

  • Androgen synthesis inhibitors: Block $CYP17$ (e.g., Abiraterone) to lower hormone levels further.

• Resistance: If cancer grows despite low testosterone, it is called resistant prostate cancer.

Non-Hormonal Treatments for Metastatic Diseases

• Chemotherapy: Doxotactyl is used alongside hormone therapy to improve survival in metastatic castration-sensitive cases.

• Radioligand Therapy (Plutico): Targeted radiation delivered through the bloodstream. It targets PSMA (prostate-specific membrane antigen), which is highly expressed on the surface of prostate cancer cells. Treatment is preceded by a PSMA PET scan.

• PARP Inhibitors: Used for cancers with DNA repair problems, particularly those with $\text{BRCA2}$ mutations.

• Palliative Care: Palliative radiotherapy and bone-strengthening treatments are used to manage bone metastases and reduce fracture risk.

Immunotherapy and Therapeutic Vaccines

• Pembrolizumab: Immunotherapy that blocks the $PD–1$ pathway. Keynote study $921$ and Keynote study $641$ showed limited benefit in general cohorts but revealed effectiveness in specific subgroups (e.g., microsatellite instability or mismatch repair deficiency).

• Provenge (Sipuleucel-T): The first approved immunotherapy vaccine for metastatic castration-resistant prostate cancer with minimal symptoms.

  • Process: Immune cells are collected via leukapheresis, exposed to a fusion of prostatic acid phosphatase and GM-CSF (an immune wake-up signal), and infused back into the patient.

  • Results: Median survival of $25.8\,\text{months}$ versus $21.7\,\text{months}$ for placebo ($22\%$ relative reduction in risk of death).

  • Availability: FDA approved; however, EU marketing authorization was withdrawn in $2015$ for undisclosed commercial reasons.

Gene Fusions and Ongoing Research

• Gene Fusion Discovery ($2005$): A fusion involving the $ER$ gene and $TMPRSS2$ (which responds to androgens) drives abnormal gene activity in many prostate tumors.

• Clinical Use: This fusion can be detected in urine alongside PSA. It is not used for general population screening but can act as a decision tool to determine if a biopsy is necessary for those with raised PSA.

Survival Trends and Public Context

• Historical Improvement: Survival rates have improved over four decades due to public awareness campaigns and treatment advances.

• Survival Statistics:

  • Early detection: Nearly $100\%$ of patients survive at least one year; more than $84\%$ live five years or longer.

  • Advanced diagnoses (especially in those > 80 years old): Significantly lower survival rates.

• Importance of Early Detection: Patients are encouraged to move past the fear of examination and talk to GPs about symptoms early to ensure curable outcomes.

Questions & Discussion

• Question: The speaker asks if there are any questions regarding the diagnostic pathway, digital pathology, or specific treatments like brachytherapy.

• Response: No specific audience questions were recorded in the transcript; the session concludes with a final encouragement for students to monitor their health and family histories as they age.